2 free · then £5–£99/mo · you pick the speed

Never miss a market event for a stock or competitor you're tracking

Pick a drug, company, disease, or class. The moment something material happens — FDA decision, Phase 3 readout, earnings shock, 8-K, patent ruling — we ship you a sourced AI brief. First 2 subscriptions free. After that, price scales with how fast you want delivery — or go Pro (£199/mo) for unlimited.

🐢
Weekly
every Mon 8am UTC
£5/mo
🚶
Daily
every day 8am UTC
£5/mo
🏃
Hourly
< 1 hour
£25/mo
Instant
< 60 seconds
£99/mo

First to know

FDA decisions, Phase 3 readouts, 8-Ks, patent rulings, AdComm votes — in your inbox within 60 seconds of the source posting.

🎯

Triaged for you

Six-dimension relevance score ranks every event against your topic. Sub-threshold noise stays out. Only signal reaches you.

🔍

Cited, not hallucinated

Every numeric claim ends with a footnote linking to its primary source. Uncited claims are dropped before delivery.

Create your subscription

Tell us what to monitor and how to reach you. We'll send a confirmation with your private feed URL.

A drug, brand, generic, company, disease, therapeutic area, or pharmacological class.

We use this to confirm your subscription and (for the email channel) send briefs. Never sold or shared.

Role + organisation. Helps us tune relevance scoring for your context.

Use case in one line. Used to improve filter quality.

By subscribing you agree to our Terms and Privacy Policy. We do not sell or share your data. One-click unsubscribe in every email.

How it works

  1. Scout pulls every press release, FDA/EMA action, SEC filing, and major trade-press article every 10 minutes. ~200 sources, deduplicated.
  2. Reader extracts the structured event — what happened, to which drug or asset, with which numbers, at which stage.
  3. Matcher compares the event against your subscription topic. Direct match, competitor match, indirect-class match — each scored.
  4. Writer produces a 5-stage competitive-intelligence brief scoped to your context: implications, comparators, projected impact, suggested next moves.
  5. Delivery — email or feed — only if relevance is above your threshold. No spam, no noise.

FAQ

Is this actually free?

Yes. No payment, no card. We do not sell data. Premium tiers may exist later for enterprise volume or custom analysts, but the core alert stream is free.

Where does the data come from?

Public sources only: FDA, EMA, SEC EDGAR, USPTO, ClinicalTrials.gov, company investor-relations newsrooms, peer-reviewed press releases, FiercePharma, EndPoints, STAT, BioPharma Dive, Reuters Health. Full data-sources page.

How accurate is the AI relevance scoring?

We rate every event 0–100 against your topic. Default threshold for delivery is 50. You can tune it in your confirmation email (low = more events, high = only highest-signal). Most subscribers settle at 60–70.

Can I subscribe to multiple topics?

Yes — fill out the form once per topic. Each gets its own private feed URL. Or just put a comma-separated list in the topic field and we'll detect the multiple targets.

How is this different from Google Alerts?

Google Alerts gives you raw URLs. We give you AI-scored relevance, structured event data (drug, phase, stage, sponsor), and a written brief with implications. Built specifically for pharma — vocabulary, sources, and ranking are tuned for the industry.